Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Voon Ong

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 31, 2026
Metabolism and excretion pathways of CD388, a novel drug-fragment crystallizable conjugate for prevention of seasonal or pandemic influenzaJan Snoeys, Grayson Hough, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy|March 21, 2018
Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrataJustin C Bader, Elizabeth A Lakota, Shawn Flanagan, et al.
Rheumatology (Oxford, England)|July 27, 2021
Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosisJulia Spierings, Svetlana I Nihtyanova, Emma Derrett-Smith, et al.
The Journal of Antimicrobial Chemotherapy|April 30, 2025
Activity of rezafungin against Candida aurisJeffrey B Locke, David Andes, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy|August 30, 2017
Pharmacological Basis of CD101 Efficacy: Exposure Shape MattersElizabeth A Lakota, Justin C Bader, Voon Ong, et al.
Journal of Medicinal Chemistry|January 17, 2014
Structure-based design of new dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2,4-diaminoquinazolinesThanh Lam, Mark T Hilgers, Mark L Cunningham, et al.
Antimicrobial Agents and Chemotherapy|May 26, 2010
Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjectsGraeme Moyle, Marta Boffito, Albrecht Stoehr, et al.
Clinical and Experimental Rheumatology|November 6, 2014
Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosisNavjyot Hansi, Nora Thoua, Maresa Carulli, et al.
Annals of the Rheumatic Diseases|January 20, 2018
Changes in macrophage transcriptome associate with systemic sclerosis and mediate <i>GSDMA</i> contribution to disease riskAida Moreno-Moral, Marta Bagnati, Surya Koturan, et al.
Rheumatology (Oxford, England)|February 5, 2017
Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosisLesley-Anne Bissell, Marina Anderson, Malcolm Burgess, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 31, 2026
Metabolism and excretion pathways of CD388, a novel drug-fragment crystallizable conjugate for prevention of seasonal or pandemic influenzaJan Snoeys, Grayson Hough, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy|March 21, 2018
Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrataJustin C Bader, Elizabeth A Lakota, Shawn Flanagan, et al.
Rheumatology (Oxford, England)|July 27, 2021
Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosisJulia Spierings, Svetlana I Nihtyanova, Emma Derrett-Smith, et al.
The Journal of Antimicrobial Chemotherapy|April 30, 2025
Activity of rezafungin against Candida aurisJeffrey B Locke, David Andes, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy|August 30, 2017
Pharmacological Basis of CD101 Efficacy: Exposure Shape MattersElizabeth A Lakota, Justin C Bader, Voon Ong, et al.
Journal of Medicinal Chemistry|January 17, 2014
Structure-based design of new dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2,4-diaminoquinazolinesThanh Lam, Mark T Hilgers, Mark L Cunningham, et al.
Antimicrobial Agents and Chemotherapy|May 26, 2010
Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjectsGraeme Moyle, Marta Boffito, Albrecht Stoehr, et al.
Clinical and Experimental Rheumatology|November 6, 2014
Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosisNavjyot Hansi, Nora Thoua, Maresa Carulli, et al.
Annals of the Rheumatic Diseases|January 20, 2018
Changes in macrophage transcriptome associate with systemic sclerosis and mediate <i>GSDMA</i> contribution to disease riskAida Moreno-Moral, Marta Bagnati, Surya Koturan, et al.
Rheumatology (Oxford, England)|February 5, 2017
Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosisLesley-Anne Bissell, Marina Anderson, Malcolm Burgess, et al.
Pageof 5